“This milestone is several years in the making and reflects our continued commitment to, and investment in, bringing the curative intent of cell therapy to patients.” “The FDA approval of our commercial viral vector manufacturing facility further strengthens our global cell therapy manufacturing network with the addition of an in-house capability to produce a crucial element in the CAR T process, which is especially important as patient demand continues to grow,” said Christi Shaw, Chief Executive Officer of Kite. Over 10,000 patients have been treated with Kite’s CAR T-cell therapies globally through more than 300 authorized treatment centers around the world, including 117 of the leading cancer hospitals in the U.S. ![]() Once an individual therapy is created for a patient, the cells are carefully preserved, packed and sent back to the hospital to be infused back into the patient. During this process, a viral vector is used to encode the CAR in the patient’s T-cells so the engineered T-cells can recognize and attack the patient’s cancer cells in certain types of blood cancers. The cells are removed through a process similar to donating blood and sent to Kite’s specialized manufacturing facilities where they are modified with a Chimeric Antigen Receptor (CAR). Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, augmenting its strong external supply partners.ĬAR T-cell therapies are one-time treatments individually made starting from a patient’s own white blood cells, called T-cells. Viral vectors are key components needed to manufacture Kite’s cell therapies to treat certain blood cancers. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. In-house Viral Vector Supply Supports Continued Reliable Delivery of Kite’s CAR T-cell Therapy Products. Kite is the Only Cell Therapy Company with In-House Viral Vector Manufacturing Capabilities for Both Commercial Products and Clinical Trials. ![]() Viral Vector Facility Further Strengthens Vertical Integration of Kite’s Global CAR T-cell Therapy Manufacturing Network, Supports Growing Demand of Company’s Blood Cancer Treatments.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |